Sana Biotechnology (SANA) Operating Income (2020 - 2026)

Sana Biotechnology has reported Operating Income for 7 years, with the latest figure at -$48.6 million in Q1 2026.

• Quarterly Operating Income rose 3.98% year-over-year to -$48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.3 million (down 16.78% YoY) and the FY2025 annual result came in at -$250.3 million, up 8.21% from the prior year.
• Operating Income improved to -$48.6 million in Q1 2026 per SANA's latest filing, from -$61.2 million in the prior quarter.
• Over five years, Operating Income peaked at -$2.2 million in Q3 2023 and troughed at -$116.3 million in Q2 2023.
• A 5-year average of -$66.9 million and a median of -$61.8 million in 2024 frame the typical range for Operating Income.
• The sharpest annual moves came in 2023 and 2024: Operating Income surged 97.47% in 2023, then slumped 2731.77% in 2024.
• Over 5 years, Operating Income stood at -$81.8 million in 2022, then fell by 10.8% to -$90.6 million in 2023, then jumped by 43.87% to -$50.9 million in 2024, then dropped by 20.31% to -$61.2 million in 2025, then grew by 20.56% to -$48.6 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$48.6 million, -$61.2 million, and -$43.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.